LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Starting on October 16, 1963, the Ad Hoc Committee to End Discrimination organized pickets and sit-ins at the Mel's Drive-In locations in San Francisco, Oakland, and Berkeley over the fact that while the restaurant would serve food to African Americans and hired them as cooks, they were not allowed to work "up front" where they could be seen by white customers. More than 100 protesters were arrested. The picketing ended when Harold Dobbs, Mel's Drive-In co-founder who was serving as a San Francisco City supervisor at the time, settled with the protesters and began to allow black workers upfront.
== History == The forerunner of the present-day company was called Kyowa Hakko Kogyo Co., Ltd (協和醱酵工業株式会社, lit. 'Coordinated Fermentation Industry Share Company') and was established on July 1, 1949. The company merged with Kirin Pharma Co., Ltd., on October 1, 2008 to form Kyowa Hakko Kirin (KHK) with plans to spin off the bio-chemical business into Kyowa Hakko Bio. On July 11, 2014, the KHK subsidiary, ProStrakan Group (based in Scotland), acquired Archimedes Pharma from the Novo Nordisk Foundation for $394 million. In 2019, Kirin Holdings acquired 95% stake in Kyowa Hakko Bio which is Kyowa Kirin's subsidiary corporation. The entity was renamed "Kyowa Kirin Co., Ltd.", replacing its prior name of Kyowa Hakko Kirin Co., Ltd. In November 2022, Kyowa Kirin announced plans to spin its International Established Medicines portfolio, consisting of 13 brands, into a new joint venture with German company Grünenthal. The joint venture would expand Grüenthal's already extensive pain management portfolio, while Kyowa Kirin saw it as a financial benefit and an opportunity to expand the brands. In October 2023, Kyowa Kirin acquired a Britain-based biopharmaceutical company, Orchard Therapeutics, for $478 million, aiming to expand their portfolio.
Arenobufagin is believed to play a role in the regulation of the transport of water and electrolytes across cell membranes under physiological conditions. Experimental results show that Arenobufagin inhibits the sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) . It is one of the most potent blockers that are known to science, along with ouabain. It has been suggested that uncharged and non-polar amino acids may participate in the binding of arenobufagin to the extracellular surface of the ATPase. If this is the case, the steroid nucleus of arenobufagin probably also contributes to the binding. Furthermore, the presence of a sugar group in ouabain and the absence of one in arenobufagin suggests that it may me more lipophilic that ouabain and as such form a more stable complex with the Na+-K+ pump. Besides its effects on the Na+-K+ pump, arenobufagin also has some other effects on cells, which were discovered in experiment with cancer cell lines. It causes apoptosis by tempering with mitochondria. In cells treated with it, a decreasing mitochondrial potential was detected (in a dose-dependent manner), as well as a high Bax/Bcl-2 ratio, which is associated with apoptosis, or programmed cell death. Bax translocation from cytosol to mitochondria was also found to be increased. In addition to these effects, arenobufagin also induces morphological changes in organelles, blebbing of plasma membrane, shrinkage of nuclear membrane and chromatin condensation. These observation also indicate the occurrence of apoptosis.
=== Bay of Bengal === India’s size and position means it has multiple roles in the southern route, both as a destination country and transit point for further destinations. The UNODC has estimated that 54% of the heroin in India is produced domestically, while 45% originates from Afghanistan. India is particularly vulnerable to the southern route due to its western border with Pakistan. Near this border, in the western Indian states of Punjab and Haryana, is where many of the heroin seizures occur. In 2012, 105 kg of drugs were seized, which had been trafficked from Pakistan along rail routes. In 2013 alone, the Indian Narcotics Control Bureau reported seizures totalling 4,609 kg. Data collected through seizures by various authorities has confirmed India as a transit country for Southeast Asia, West Africa and North America. Bangladesh also faces significant problems due to drug trade through the Indian Ocean and India. The country suffers from illicit drug use among its population, such as in Dhaka where there are an estimated 2.5 million people using drugs. India is a large provider of heroin to the Bangladeshi market, and it is trafficked over the western and eastern borders. However, it is unclear whether the heroin originates from Afghanistan or India, as this data has not been sufficiently collected. Both India and Bangladesh are becoming ever more dependent on maritime trade, with these states importing over US$52 million and US$447 million respectively.
== General care == The skin is the largest organ in the human body, protecting against pathogens, irritants, ultraviolet light, and mechanical injury, while also regulating temperature and water release as perspiration. Simple habits like washing and applying lotion may provide benefit, but little is known scientifically about the clinical efficacy of these practices. Skin care routines, even in hospitals and medical facilities, may be based on personal beliefs, preferences, and local circumstances rather than current evidence or best practices.
Sources: en.wikipedia.org
=== Eggsquis === Eggsquis is a midscale chain of restaurants in Quebec and Ontario. As of 2018, there are 39 outlets, which are primarily in Quebec. It specializes in egg dishes, from bacon and eggs to omelettes. The first Eggsquis restaurant was opened by Elias Stergiou in Sherbrooke, in 1995. In 2010, the owners of the restaurant chain Chez Cora took Eggsquis to court, claiming that some of the dishes at its Mascouche location had been copied from Cora's, including the names of the dishes.
=== Non-refrigerated fresh tempeh === Tempeh can be sold and consumed fresh within 48 hours once removed from its incubator. It is commonly transported to the market in its incubation container (e.g. polyethylene bag, banana leaf wrapper, etc.) and placed in the shade. In areas with warmer climates, tempeh can be kept at room temperature for one to three days before it becomes overripe. In locations with more temperate temperatures, it can keep for one to four days but will usually need to be refrigerated to prevent spoilage.
==== Wagyu ==== Most of today's Wagyu are improved Wagyu (改良和牛, kairyō wagyū) that have been fixed as breeds through crossbreeding with foreign breeds. There are four breeds of improved Wagyu as follows:
rhEPO has been used illicitly as a performance-enhancing drug. It can often be detected in blood, due to slight differences from the endogenous protein; for example, in features of posttranslational modification.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.